Glutamate Receptor Antagonists - Pipeline Insight, 2024

Glutamate Receptor Antagonists - Pipeline Insight, 2024

DelveInsight’s, “Glutamate Receptor Antagonist - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Glutamate Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glutamate Receptor Antagonist Understanding

Glutamate Receptor Antagonist: Overview

Glutamate Receptor Antagonist can be broadly divided into two types: agents that block the NMDA receptor and those that block the AMPA receptor. Antagonists of the NMDA receptor act either by competitive antagonism at the glutamate-binding site or by noncompetitive antagonism at the glycine, phencyclidine (PCP)-, and magnesium-binding sites.

Preclinical, clinical, and other (e.g., genetic) evidence support the concept that migraine susceptibility may at least partially result from a glutamatergic system disorder. Therefore, the receptors of the glutamatergic system are considered relatively new targets for investigational drugs to treat migraine. Investigational and established Glutamate Receptor Antagonist (GluRAs) have been shown to possess antinociceptive properties in preclinical models of trigeminovascular nociception and have been evaluated in clinical trials.

Nicotine dependence is the primary motivational factor perpetuating the tobacco smoking habit that is one of the leading preventable causes of morbidity throughout the world. Metabotropic glutamate 5 receptor antagonists may be useful in decreasing the reinforcing effects of nicotine, reducing motivation for nicotine and preventing relapse during protracted abstinence, whereas metabotropic glutamate 2/3 receptor antagonists may alleviate the depression observed during the early nicotine withdrawal phase. Metabotropic glutamate 2/3 receptor antagonists may also be therapeutics for non-drug-induced depressions.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Glutamate Receptor Antagonist R&D. The therapies under development are focused on novel approaches for Glutamate Receptor Antagonist.

Glutamate Receptor Antagonist Emerging Drugs Chapters

This segment of the Glutamate Receptor Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glutamate Receptor Antagonist Emerging Drugs

• E2007: Eisai

E2007 is a selective antagonist against the AMPA receptor (a glutamate receptor subtype). Fycompa is a first-in-class AED discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Fycompa is available in tablet form to be taken once daily orally at bedtime.

It is currently in Phase III stage of development and is being developed by Eisai.

• SLS-002: Seelos Therapeutics

SLS-002 is intranasal racemic ketamine with two investigational new drug applications for the treatment of Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder.

It is currently in Phase II stage of development and is being developed by Seelos Therapeutics.

Further product details are provided in the report……..

Glutamate Receptor Antagonist: Therapeutic Assessment

This segment of the report provides insights about the different Glutamate Receptor Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Glutamate Receptor Antagonist

There are approx. 40+ key companies which are developing the Glutamate Receptor Antagonist. The companies which have their Glutamate Receptor Antagonist drug candidates in the most advanced stage, i.e. Phase III include, Eisai.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Glutamate Receptor Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glutamate Receptor Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glutamate Receptor Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glutamate Receptor Antagonist drugs.

Glutamate Receptor Antagonist Report Insights

• Glutamate Receptor Antagonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glutamate Receptor Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Glutamate Receptor Antagonist drugs?
• How many Glutamate Receptor Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Glutamate Receptor Antagonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glutamate Receptor Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glutamate Receptor Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Algernon Pharmaceuticals
• Relmada Therapeutics
• Axsome Therapeutics
• Aptinyx
• Seelos Therapeutics
• Biohaven Pharmaceuticals
• Eisai

Key Products

• NP-120
• REL-1017
• AXS-05
• NYX-458
• SLS-002
• BHV-5000
• E2007